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Abstract 
 
Influenza virus type A (IVA) is the etiologic agent responsible for the febrile respiratory 
illness referred to as the flu.  Seasonal and occasionally pandemic IVA-associated illness is a 
significant cause of morbidity and mortality worldwide, and presents a significant burden to 
the healthcare system.  Our previous work showed that the propagation of IVA required the 
lysosomal protease cathepsin B (CTSB), though the mechanism behind this dependency was 
not elucidated.  This study further assessed the role of CTSB by examining different stages in 
the viral lifecycle for defects using CTSB-deficient (CTSB-/-) macrophages and the CTSB-
specific chemical inhibitor CA-074 Me (CaMe) in human lung epithelial cells.  CTSB-/- and 
CA-074 Me-treated cells showed no defect in either the uptake of virus particles, nor their 
replication following endosomal escape compared to wildtype or non-treated cells, 
respectively.  However, CTSB-/- and CA-074 Me-treated cells had significantly less 
hemagglutinin (HA) protein both inside and on the surface of infected cells, as determined by 
both Western blotting and confocal immunofluorescence microscopy.  These results suggest 
that CTSB is required for a step(s) in the viral lifecycle following entry into host cells, either 
before or during the synthesis of viral proteins, and possibly during the transport of viral 
components to the host membrane.  Further work is necessary to determine the mechanistic 
details of these observations, and may yield novel potential therapies for influenza infections. 
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Chapter 1: Introduction 
1.1 Influenza A Virus  
Viruses are obligate infectious particles composed of genetic material surrounded by a 
protein capsid and in some cases a lipid envelope.  Influenza viruses can be divided into three 
genera within the Orthomyxoviridae family, each containing a single species: Influenza virus 
A, B and C.  Infection in humans results in a febrile disease characterized by malaise, cough 
and headache, commonly referred to as the “flu” [1].  While illness resulting from influenza 
virus infection is usually self-limiting – resolving within a week – some isolates are capable 
of causing severe illness and even death [2].  Complications resulting from infections can be 
equally serious, and include pneumonia due to secondary bacterial infections, pulmonary and 
cardiovascular disease [3, 4].  In addition to humans, influenza viruses also infect a number 
of vertebrates, including birds, pigs, and other mammals.  Infections in domestic livestock 
have occasionally resulted in the transfer of influenza to humans, and subsequent outbreaks 
of the disease [5].  Infections in migratory birds pose the greatest threat, and raise concerns of 
a global influenza pandemic. 
Although all three species of influenza virus have the capacity to infect humans, infections 
with influenza virus type A (IVA) are the most common [6, 7].  In the most recent flu season, 
the Centers for Disease Control (CDC) reported 86% of 22417 laboratory-confirmed 
influenza infections were due to IVA, and the remaining 14% to type B influenza virus [8] – 
type C influenza virus was rarely isolated [9].  Due to its prevalence and body of existing 
research knowledge, IVA was selected for these studies. 
1.1.1 IVA Structure 
IVA is an enveloped virus with a genome consisting of eight negative-sense single-stranded 
RNA (-ssRNA) segments (Figure 1).  These genome segments code for eleven proteins, eight 
of which are packaged into progeny virions [10].  Two of these proteins, hemagglutinin 
(HA), which mediates entry, and neuraminidase (NA), which facilitates progeny virion 
release from cells [11, 12], are expressed on the surface of virions as spike glycoproteins and 
are therefore the antigenic determinants against which humoral immune responses are raised.   
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Figure 1 – Structure of influenza virus  
The surface of the enveloped virion is studded with hemagglutinin (HA) and neuraminidase 
(NA) envelope glycoproteins.  Beneath the host-derived lipid envelope, matrix (MA) proteins 
surround the ribonucleoprotein core, which contains the negative-sense segmented RNA 
genome of the virus.  These eight segments encode viral polymerase subunits (PB2, PB1, 
PA), hemagglutinin protein (HA), nucleoprotein (NP), neuraminidase (NA), matrix and M2 
proteins (M), and non-structural proteins 1 and 2 (NS). 
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A third transmembrane protein, ion channel M2, functions during viral entry and budding 
[13-15].  Beneath the envelope, matrix protein (MA/M1) gives structure to the virion and acts 
as a bridge between the ribonucleoprotein core and the lipid envelope [16-18].  The 
ribonucleoprotein core is a complex of the RNA genome as well as nucleoprotein (NP) and 
viral polymerase proteins, and lies at the center of the virion.  NP binds the genome segments 
and plays essential roles in replication [19, 20], whereas the viral RNA polymerase proteins 
(PB1, PB2, PA) are responsible for the transcription and replication of the genome [21, 22].  
Three additional proteins are expressed during infection but not included in mature virions: 
non-structural protein 1 (NS1), which functions to evade host immune responses [23-25]; 
NS2 (also known as nuclear export protein, or NEP), which mediates the nuclear export of 
viral genomes [26]; and PB1-F2, which induces cell death in the host [27, 28].  Assembled 
viral particles are pleomorphic, and can be either spherical with a diameter of ~100 nm [29], 
or filamentous with dimensions of ~100 nm x 20 µm [30].  Although both forms have been 
noted in the literature for several decades, the significance of this divergence in morphologies 
is poorly understood at this time; recent work suggests both forms possess a single copy of 
the viral genome [31] and are comparably infectious [32]. 
1.1.2 IVA Genetics 
IVA comprises several distinct subtypes based on two antigenic determinants on the viral 
surface, where isolates are designated a number depending on what variant of the protein is 
present.  This nomenclature is then expressed in the form of H(n)N(n), where n represents the 
variant of each surface antigen (hemagglutinin, H; neuraminidase, N).  As of 2013, there are 
seventeen H and nine N subtypes, yielding over one hundred and fifty theoretical 
combinations [33].  Genetic alterations in these subtypes has also necessitated the further 
classification of strains within subtypes to include information such as the location, year and 
isolate number of the virus [10]. 
IVA owes this great variability to its genetic nature.  Mutation rates in type B viruses are less 
than half of those in IVA [34], suggesting that IVA’s ability to mutate rapidly is a driving 
force behind this evolution.  Mutations give rise to new strains and subtypes of IVA to which 
the host immune system is naïve.  This strategy effectively subverts immunological memory 
responses produced by prior infections with other strains and subtypes of the virus [35].  For 
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this reason, humans can become ill from IVA multiple times; this is also the basis for 
influenza vaccines being administered annually as opposed to a single time.  Pandemics can 
occur if the human population at large has little or no immunity against new viral strains or 
subtypes resulting from mutations [36].  Mutations are therefore not only significant for viral 
evolution, but epidemiology as well. 
Mutations can arise from two processes: antigenic drift and antigenic shift [37, 38].  
Antigenic drift refers to the gradual change in a gene resulting from small changes, such as 
point mutations, over time.  These small mutations in surface antigens can impair recognition 
by the host’s immune system by subtly altering the shape of viral antigens.  Antigenic shift is 
a more dramatic process, involving the exchange of genetic information between two 
different viruses which have co-infected the same cell [39], a phenomenon facilitated by the 
segmented nature of the influenza genome.  Although far less common than antigenic drift, 
antigenic shift can result in unpredictable combinations of genes to produce a new virus.  A 
recent example of this was seen in the 2009 pandemic H1N1 virus, which contains genes 
from avian, swine and human influenza viruses [40].  Fortunately however, the strain lacks 
mutations known to increase pathogenicity, and the swine-origin antigenic determinants 
share considerable homology to a virus circulating in humans. 
1.1.3 IVA Lifecycle 
The lifecycle of IVA begins with receptor binding at the surface of target cells (Figure 2).  
Using the spike glycoprotein HA, virions bind to sialic acid moieties on the host plasma 
membrane [41]; airway and respiratory tissues are rich in sialic acid, thus explaining why 
influenza is a respiratory pathogen [42-44].  Receptor binding triggers the uptake of the 
virion via endocytosis into an endosome [45, 46].  Following entry, the virion-containing 
early endosome is trafficked towards the nucleus and matures into a late endosome, an event 
accompanied by acidification of the compartment [47, 48].  At a sufficiently acidic pH (~5-
6), HA undergoes an irreversible conformational change to mediate the fusion of the viral 
envelope and endosomal membrane, thus releasing the ribonucleoprotein core into the host 
cytoplasm [49].  Once in the cytoplasm, the core dissociates and the newly freed RNA 
genome is actively imported into the nucleus, where replication to generate progeny genomes 
and transcription of mRNAs take place [50-52].  
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Figure 2 – Overview of the IVA lifecycle 
Using the envelope glycoprotein HA, incoming IVA virions bind sialic acid receptors on the 
surface of host cells, triggering endocytosis.  Virion-containing endosomes migrate towards 
the nucleus becoming increasingly acidic.  At a sufficiently low pH, a conformational change 
in HA triggers the fusion of viral and endosomal membranes, thus releasing the genome-
containing ribonucleoprotein core into the host cytosol.  After being imported into the 
nucleus, the viral genome begins replication and mRNA synthesis.  While inhibiting host 
protein synthesis, the virus selectively translates viral proteins in the cytoplasm; 
transmembrane proteins are translated on rough endoplasmic reticulum.  Spike glycoproteins 
are trafficked through the Golgi and to lipid raft domains in the plasma membrane, where 
they direct the assembly and release of progeny.  The accumulation of viral proteins and 
genomes progressively increases membrane curvature forming a bud-like structure.  M2-
mediated scission of viral envelopes and host membrane yields virions with all viral 
components enclosed.  After NA cleaves bonds between virion-associated HA and sialic acid 
on the host membrane, progeny are released into the extracellular medium.  
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In the nucleus, viral RNA-dependent RNA polymerase initiates the replication of the genome 
by producing a complementary (+)-sense template in a primer-independent fashion which 
can then be used in the generation of progeny genomes [53, 54].  Transcription of viral 
mRNAs begins with the seizure of cellular pre-mRNAs by viral polymerase, which are then 
catalytically cleaved to liberate their 5’ caps.  Host-derived 5’ caps are then used to prime 
transcription of viral genes, which end in short poly-U stretches that are repeatedly copied by 
polymerase, yielding a viral mRNA which bears both a 5’ cap and 3’ poly-A tail [55, 56].  
During this time, the virus orchestrates a number of mechanisms that ensure the preferential 
translation of viral mRNAs over cellular mRNAs [57].  By blocking host mRNA export from 
the nucleus [58, 59], host mRNA translation at both initiation and elongation stages [60], and 
by producing mRNAs which contain sequences that promote their preferential translation 
[57, 61, 62], the virus both eliminates host protein synthesis and promotes translation of viral 
proteins [63].  
Protein-coding mRNAs are exported from the nucleus to the cytoplasm where they are 
translated on free ribosomes, or in the case of transmembrane proteins such as HA and NA, 
on rough endoplasmic reticulum [64].  Following protein synthesis and folding, HA and NA 
are transported to the plasma membrane via an exocytic pathway, where they are targeted to 
cholesterol-rich lipid raft microdomains, where progeny virions are assembled and released 
[65, 66].  Accumulation of HA at the membrane triggers the nuclear export of progeny 
genomes [67].  The process of nuclear export seems to rely on at least three different viral 
proteins: NS2/NEP, MA/M1 and NP [68-72].  Once in the cytoplasm, progeny genomes are 
trafficked independently of membrane proteins using the host cytoskeleton and Rab11-
positive recycling endosomes [73-75]. 
Once at the site of assembly and release, genome segments are packaged in a specific rather 
than random manner [31, 76, 77].  Although poorly understood at this time, the process of 
budding and release is thought to begin with deformation of the host membrane, possibly due 
to HA-induced membrane curvature [78].  The cytoplasmic tails of HA and NA are thought 
to interact with M1 [79, 80], which subsequently interacts with progeny genomes [17, 81].  
This process results in a budding structure which remains connected to the host plasma 
membrane.  For virions to be released from host cells, membrane scission is required to 
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separate the two structures, enclosing ribonucleoprotein complexes in a fully formed viral 
envelope.  Unlike other enveloped viruses, IVA does not utilize host machinery for this 
process [82-84]; instead, the viral M2 protein mediates the membrane scission of progeny 
[15, 85].  Although no longer sharing the same membrane, newly formed virions remain 
attached to the host cell via interactions between HA and sialic acid at the plasma membrane.  
These bonds are cleaved by NA, allowing virions to be released into the extracellular 
environment for the next infection cycle [12, 86]. 
1.1.4 Hemagglutinin 
The spike glycoprotein hemagglutinin is an essential component in the IVA lifecycle.  HA is 
the most abundant (~80 %) glycoprotein on the surface of virions [37, 87], and was named in 
1941 after its ability to aggregate red blood cells [88].  Unknown at the time, this protein 
would later be recognized as mediating the binding event which initiates viral entry into a 
host cell [89].  HA interacts with host sialic acid moieties using a small, highly conserved 
binding pocket at the outermost tip of the protein [90, 91].  Although the binding affinity of 
this interaction is weak (Kd ~3 mM), the abundance of virion-associated HA greatly increases 
its collective avidity, resulting in a tight bond between virion and host cell [92-94]. 
Following endocytosis, HA is again essential for successful infection, but in a manner 
completely independent of its receptor binding functions.  In addition to triggering the 
endocytosis of viral particles [45, 46], HA facilitates their escape from endosomes resulting 
from internalization.  As virion-containing endosomes are trafficked from the plasma 
membrane towards the nucleus, their interior becomes increasingly acidic [95]; paradoxically 
however, this event is not only advantageous to the virus, but required for its successful 
entry.  When endosomes reach an acidic pH of ~5-6, HA undergoes a conformational change 
exposing a hydrophobic fusion peptide previously sequestered at neutral pH [96-98].  
Insertion of this peptide into the endosomal membrane triggers the fusion of the membrane 
and viral envelope, forming a pore which allows passage of virion contents to the host 
cytoplasm [99-101].  Chloroquine, which blocks endosomal acidification, effectively inhibits 
viral replication by preventing conformational changes in HA and subsequent membrane 
fusion, underscoring the importance of HA in this process [102]. 
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After mRNA synthesis, HA is synthesized on rough endoplasmic reticulum as a ~75 kDa 
precursor protein which is transported to the plasma membrane through the Golgi apparatus 
using host vesicular transport systems [73-75, 103], and is intrinsically targeted to 
cholesterol-rich lipid raft microdomains in the plasma membrane using sequence 
determinants [65, 104-107].  Interactions with viral transmembrane proteins serve as 
scaffolding for the assembly of virions; since HA is the most abundant of these proteins, it 
has considerable influence in the assembly of progeny [108].  HA accumulation at the 
membrane serves as a signal to export progeny genomes from the nucleus for packaging into 
virus particles, a process which also involves HA [67, 109].  Although the importance of HA 
in the process of budding remains controversial [78, 110], if any virions are released in its 
absence, they will nonetheless remain non-infectious since HA mediates cell entry.  
1.2 Cathepsin B   
Cathepsins are a group of proteases found in animal cells which catalyze reactions that 
degrade proteins.  Over a dozen members belong to this family, all of which are 
distinguished by their structure, function and substrate [111].  Cathepsin B (CTSB) is one 
such member; a lysosomal cysteine protease coded by the CTSB gene, cathepsin B is 
involved in protein turnover.  Over the last two decades however, an increasing body of 
research has revealed that CTSB plays additional roles in trafficking tumor necrosis factor 
(TNF)-α containing vesicles [112], NALP3 activation and inflammasome formation [113, 
114], and cell death [115].  In light of this, it is perhaps not surprising that CTSB has been 
implicated in many diseases including arthritis [116], cancer [117] as well as chemotherapy 
strategies [118, 119], and pancreatitis [120]. 
1.2.1 Background 
CTSB is one of the most abundant lysosomal proteases and is found ubiquitously in 
eukaryotic cells [121, 122].  It functions as an endopeptidase at neutral pH and an 
exopeptidase at acidic pH (~5), participating in both early and late stages of endosomal 
proteolysis [123].  In addition, CTSB has also been found in the cytoplasm [124], at the cell 
surface [125], and in the nucleus [126].  Apart from degradative roles, CTSB is responsible 
for the proteolytic cleavage of ricin A [127], soft connective tissue collagen [128], and 
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trypsinogen [129].  Cytosolic release of CTSB is also implicated in multiple cell death 
pathways by cleaving pro-apoptotic proteins such as Bid, although other mechanisms have 
also been reported [124, 130-133]. 
Given the potentially destructive nature of cathepsins, their enzymatic activities are tightly 
regulated within cells to prevent inadvertent activity.  Multiple defence strategies are utilized, 
including the compartmentalization of cathepsins in organelles, instability at neutral pH, and 
endogenous inhibitors [134].  Cystatins are a group of cysteine protease inhibitors which 
serve to prevent the unwanted activity of proteases like CTSB in the cytoplasm or 
extracellular space [135].  More recently, synthetic inhibitors have proven invaluable tools in 
research due to their target specificity; the cell-permeable CTSB-inhibitor CA-074 Me 
(CaMe) is one such highly specific inhibitor [136-139].  However, it should be noted that 
CaMe also inhibits cathepsin L under reducing conditions [140]. 
A number of pathologies can result from inappropriate CTSB activity.  There is a well-
established link between elevated CTSB activity and the metastasis of cancers due to 
proteolytic degradation of the extracellular matrix and activation of other cascades [141-144].  
Similar mechanisms may be the cause of CTSB-mediated joint destruction in the pathology 
of rheumatoid arthritis [145-148].  On the other hand, impaired CTSB function has been 
linked to Alzheimer’s disease, where CTSB performs a protective role by reducing plaque 
formation through proteolytic activity [149].  CTSB inhibition has also been shown to impair 
the lysosomal degradation of lipids, the abnormal accumulation of which can result in 
atherosclerosis [150]. 
1.2.2 The role of Cathepsin B in viral lifecycles 
Since viruses have a limited coding capacity – some restricted to less than a dozen genes – 
they are highly economical by nature.  As a result, viruses frequently evolve proteins which 
fulfill multiple functions, or develop cleaver strategies to use host resources.  As such, 
several viruses have found a use for host CTSB in lieu of a virally-encoded factor, though the 
capacity in which CTSB is utilized in their lifecycles may differ between viruses. 
CTSB has been shown to be an essential host factor in the lifecycle of Ebola virus [151]; 
inhibition of CTSB reduced infection by >90%.  Similar to IVA, Ebola virus gains access to 
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cells via endosomes and requires fusion of the viral envelope and the endosomal membrane 
in order to escape from the endosome into host cytoplasm [152].  To do so, the virus utilizes 
CTSB to catalytically activate its membrane glycoprotein [153, 154].  Thus, although not 
required for viral replication [155], CTSB is essential in the process of viral entry.  Nipah 
virus [156], Moloney murine leukemia virus [138], and feline coronavirus [157] use CTSB in 
a similar fashion. 
Unenveloped reovirus does not require CTSB to activate fusion proteins, but instead for the 
proteolytic disassembly of the viral capsid while in host endosomes [136].  Adeno-associated 
virus types 2 and 8 use CTSB to cleave capsid proteins, thereby priming rapid disassembly in 
the nucleus [158].  The catalytic activity of CTSB is also involved in the optimal replication 
of Herpes simplex virus type I DNA [159].  Additionally, CTSB is required for the proper 
release of HIV virions from macrophages; when inhibited, virions are retained in intracellular 
multivesicular bodies and/or endosomes [137].  This study also showed that a CTSB 
deficiency inhibited the propagation of IVA but not enterovirus, as evidenced by 
immunofluorescence microscopy using pan-specific antibodies recognizing the respective 
viruses.  Interestingly, it has recently been reported that CTSB is elevated in the plasma and 
monocytes of HIV-positive individuals, and may be associated with HIV-associated 
neurocognitive disorders [160]. 
1.2.3 Potential involvement of Cathepsin B in lipid homeostasis  
Although not fully understood at this time, several lines of evidence suggest that CTSB and 
other members of the cathepsin family play roles in lipid metabolism [161, 162].  This is 
perhaps best substantiated by the observation that lipids accumulate within cells lacking 
cathepsins such as CTSB as a result of impaired lipid metabolism [163].  Not surprisingly, 
this intracellular accumulation of lipids has implicated CTSB in the pathology of 
atherosclerosis, a condition characterized by the progressive thickening of arterial walls due 
to the accumulation of fatty deposits.  
Interestingly, cathepsin D has been shown to be involved in the transport of endocytosed 
cholesterol from intracellular compartments to the plasma membrane [164, 165].  Inhibition 
of CTSD reduces the transcription of the cholesterol transporter ABCA1, thereby reducing 
13 
 
 
 
cholesterol transport by 70%.  This results in the accumulation of lipids within endosomes, 
closely resembling the phenotype of the lysosomal storage disorder Niemann-Pick disease 
type C (NPC); NPC is a consequence of mutations to the NPC1 gene, which codes for a 
cholesterol transporter [165-169].  Thus, it is possible that the documented observations of 
CTSB-dependent lipid accumulation might function through similar means by altering the 
expression of cholesterol transporters. 
1.3 Rationale, hypothesis and objectives 
CTSB is a lysosomal protease involved in the lifecycles of some viruses.  Recent work from 
our lab showed that CTSB is required for HIV-1 virus-like particle release, and possibly the 
propagation of herpes simplex virus 1 (HSV-1) and IVA [137].  Based on these observations, 
I hypothesize that CTSB is required for the optimal replication and/or release of influenza 
virions.  Given the various roles of CTSB in the lifecycles of other viruses, it was pertinent to 
address this hypothesis by assessing whether a CTSB-deficiency – either genetic or 
pharmacological – had any effect on different stages in the IVA lifecycle.  By examining 
viral entry, replication, HA protein production, trafficking of HA to the plasma membrane, 
and release of viral particles in CTSB-deficient cells or cells treated with the CTSB inhibitor 
CaMe, I attempted to elucidate which of these processes, if any, relied on CTSB. 
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Chapter 2: Methods 
2.1 Reagents 
The synthetic CTSB inhibitor [L-3-trans-(Propylcarbamoyl)oxirane-2-carbonyl]-L-isoleucyl-
L-proline Methyl Ester (CA-074 Me; CaMe) was purchased from Peptide Institute Inc. 
(Osaka, Japan).  Actinomycin D (ActD; A9415) and LysoTracker Red (L-7528) were 
purchased from Sigma (Oakville, Canada).  Influenza A H1N1/Puerto Rico/8/34 (PR8) was 
obtained from Dr. Mansour Haeryfar (London, Canada).   
Primary antibodies used included anti-β Actin (rabbit; Rockland #600-401-886) and anti-HA 
(mouse; sterile culture supernatant of monoclonal hybridoma H28-E23; a kind gift from Dr. 
Mansour Haeryfar; London, Canada).  Secondary antibodies used included goat anti-rabbit 
IgG IRDye 800 (Li-Cor #926-32211; Lincon, United States), goat anti-mouse IgG IRDye 
800 (Li-Cor #926-32210; Lincon, United States), and fluorescein-conjugated F(ab’)2 
fragment goat anti-mouse IgG (Jackson ImmunoResearch #115-096-146; West Grove, 
United States). 
2.2 Cell Culture 
Human lung adenocarcinoma (A549) cells were grown in DMEM supplemented with 10% 
heat-inactivated fetal bovine serum (FBS; VWR; Mississauga, Canada), 1 mM MEM non-
essential amino acid solution, 100 U/mL penicillin G, 100 µg/mL streptomycin and 1 mM 
sodium pyruvate (Sigma; Oakville, Canada).   
Bone marrow-derived immortalized macrophages (BMDIM) from C57 BL/6 mice were 
prepared from wildtype (Wt) or CTSB-/- (KO) backgrounds as described previously [112, 
170].  C57 cells were grown in RPMI 1640 supplemented with 10% heat-inactivated fetal 
bovine serum (FBS; Sigma; Oakville, Canada), 1 mM MEM non-essential amino acid 
solution, 100 U/mL penicillin G, 100 µg/mL streptomycin and 1 mM sodium pyruvate. 
All cells were grown at 37˚C in a humidified atmosphere containing 5% CO2. 
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2.3 Viral Infections 
One million cells were placed in 15 mL conical tubes and infected with PR8 at an MOI of 1, 
5 or 10 (depending on the experiment) for one hour in 1 mL of PBS rotating at 37˚C.  
Conditions with CaMe or ActD received the drug at the time of infection.  After one hour 
adsorbtion, 5 mL of complete culture medium was added to the cells (with drug, if 
applicable) and incubation continued for a further 5 hours while rotating at 37˚C.   
2.4 Western Blot 
Samples were lysed on ice for 20 minutes in cold lysis buffer (50 mM tris-HCl [pH=7.4], 150 
mM NaCl, 1 mM EDTA, 1% Triton X-100, 0.1% SDS with protease inhibitor cocktail 
[Roche; Mississauga, Canada]) and run on 10% SDS gels at a voltage of 110V for 1.5 hours.  
Following this, the gel was semi-dry transferred onto PVDF (Pall Life Sciences #BSP0161; 
Mississauga, Canada) for 1.5 hours at 18V.  Membranes were blocked in 5% (w/v) skim milk 
in tris-buffered saline (TBS; 50 mM tris-HCl, 150 mM NaCl, pH 7.5) containing 0.08% 
Tween 20 (TTBS) for one hour and probed with primary antibodies at a 1:1000 dilution in 
TTBS overnight at room temperature.  The following day, blots were washed in TTBS and 
incubated with secondary antibodies at a dilution of 1:10000 in TTBS for one hour.  Blots 
were imaged using the Li-Cor Odyssey system (Guelph, Canada). 
Densitometric analysis on Western blots was performed using the densitometry feature in 
ImageJ (NIH; Bethesda, United States).  Lanes were analyzed and the resulting histograms 
were used to measure band density by measuring the area under each peak with any 
background subtracted.  Densities of target immunoreactivities were then normalized to a 
loading control (β-actin) for data analysis. 
2.5 RT-qPCR 
Briefly, RNA was extracted from cells using TriZol (Invitrogen; Burlington, Canada) and  
0.5 µg was reverse transcribed with M-MuLV (New England Biolabs; Whitby, Canada) 
following manufacturer’s protocols using two viral gene-specific primers to yield template 
cDNA (see below).  One µL of this sample was amplified with SYBR Green PCR Master 
Mix (Invitrogen; Burlington, Canada) and quantified using a Rotor-Gene RG3000 (Corbett 
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Life Science; Kirkland, Canada) with the following cycling conditions: 94˚C for 2 min; 94˚C 
for 15 sec, 54˚C for 30 sec, and 72˚C for 30 sec with 30 cycles.  Target amplicons for the two 
genes were PCR-amplified and a standard curve of each was generated by making a series of 
ten-fold dilutions (Figure 3).  Known concentrations of amplicon were used to calculate copy 
number, and the resulting equations were used to determine the copy numbers of unknown 
samples based on Ct values as described previously [171, 172]. 
HA primers were generated from a sequence specific to the PR8 strain of influenza 
(GenBank: CY009447.1) using Primer3. 
HA Fwd/RT primer: 5’-TGCTTCAAAACAGCCAAGTG-3’ 
HA Rev primer: 5’-GCCCAGTACCTGCTTCTCAG-3’ 
MA primers were generated from a sequence reported in literature to be highly conserved 
among viral subtypes [173]. 
Matrix Fwd/RT primer: 5′-CTTCTAACCGAGGTCGAAACG-3′ 
Matrix Rev primer: 5’- GCATTTTGGACAAAGCGTCT-3’ 
2.6 Fractionation 
Crude and purified lysosome/endosome fractions were obtained using a lysosome isolation 
kit (Sigma; Oakville, Canada).  Briefly, 3 x 107 C57 cells were lysed using a Dounce 
homogenizer as directed.  Nuclei and debris were pelleted by centrifugation for 10 min at 
1000 g, and organelles (mitochondria, lysosomes, peroxisomes, endoplasmic reticulum, late 
endosomes) were isolated from the resulting supernatant by centrifugation for 20 min at 
20000 g to yield the crude fraction.  A proportion of this fraction was further purified by 
adding 8 mM calcium chloride and centrifuging for 15 min at 5000 g to yield a purified 
fraction of late endosomes/lysosomes.  These fractions were then assayed for their 
cholesterol and protein contents as described below. 
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2.7 Cholesterol Assay 
Lipids were extracted from lysed cells from Section 2.6 using the Folch method [174, 175].  
Briefly, cell lysates were added to a 2:1 chloroform-methanol solution and lipids were 
extracted by vacuum drying the organic phase.  Cholesterol content was assayed using the 
Amplex Red Cholesterol Assay Kit (Invitrogen #A12216; Burlington, Canada) following 
manufacturer’s instructions. 
2.8 Protein Assay 
Protein assays were done in tandem with cholesterol assays using a fraction of cell lysates 
prepared for the cholesterol assay (above).  Protein concentration was determined using 
Bradford reagent (BioRad; #500-0006; Mississauga, Canada) following manufacturer’s 
directions of the Bradford technique [176].  A BSA reference curve was generated with each 
replicate to give a standard curve of protein concentrations that was used to determine the 
concentration of samples. 
2.9 Immunofluorescence Microscopy 
Fifty thousand A549 cells suspended in 50 µL of PBS were seeded onto coverslips and 
allowed to attach (~1 hour).  Cells were then infected with PR8 at a high MOI (5 or ~10) by 
directly pipetting virus onto coverslips; any inhibitors indicated were added at this time.  
After a one hour adsorbtion period, 2 mL of warm media (with inhibitors, if applicable) was 
added to 6-wells containing coverslips and incubation was allowed to continue for an 
additional 4.5 hours.  At this point, LysoTracker Red was added to a final concentration of 
200 nM and coverslips were allowed to incubate for 30 min.  After the six hour infection 
period was complete, coverslips were washed in PBS and fixed in 4% formaldehyde for 17 
min.  For conditions requiring permeabilization, cells were treated with 0.25% Triton X-100 
for 10 min.  After two washes in PBS, coverslips were blocked in PBS + 1% BSA + 0.05% 
Tween 20 for one hour and then incubated in anti-HA primary antibody at a 1:10 dilution 
overnight at 4˚C.  The following day, slides were washed in PBS and incubated in secondary 
(anti-mouse FITC) at a 1:100 dilution for two hours.  Slides were then washed once more and 
incubated in Hoechst 33342 for 3 min at a 1:4000 dilution, rinsed, mounted, and viewed 
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using a Bio-Rad Radiance 2000 fluorescence microscope or a Zeiss LSM 510 confocal 
fluorescence microscope.  Images were acquired using QCapture Pro 6.0 (QImaging; Surrey, 
Canada) or Zen 2008 (Zeiss; Toronto, Canada) for the Bio-Rad Radiance 2000 and Zeiss 
LSM 510, respectively. Colocalization was assessed using the JACoP plugin for ImageJ 
[177]. 
2.10 Hemagglutination Assay 
Hemagglutination assays were performed as described previously [178].  Briefly, 1 x 106 
A549 cells were infected at an MOI of 1 in the presence or absence of CaMe (150 or 500 
µM) in a total volume of 1 mL PBS.  After one hour adsorption, PBS and virus were 
aspirated, and cells were washed twice in PBS.  Two mL of fresh serum-free DMEM with 
2.5 µg/mL trypsin was added, along with CaMe if applicable, and incubation continued for 
an additional 23 h.  Twenty four hours post-infection, supernatant was collected and 
centrifuged to pellet debris.  Fifty µL from each condition was added to 50 µL of PBS in 
triplicate and serially diluted two-fold.  A PBS-only control and a positive control using the 
stock virus were run with each replicate.  Fifty µL of a 0.5% adult chicken erythrocyte 
(Charles River Laboratories; Wilmington, United States) solution in PBS was added to each 
well and gently mixed.  After incubating 30 min at room temperature, wells were scored as 
either positive or negative, and the titre reported as the reciprocal of the highest dilution 
which yielded agglutination. 
2.11 MTT Assay 
Seventy five thousand cells in triplicate 96-wells were treated in the presence or absence of 
drug for six hours at 37˚C to reproduce conditions during infection.  After treatment, MTT 
was added to a final concentration of 0.5 mg/mL and incubation continued for an additional 2 
hours.  When incubation was complete, culture medium was aspirated and 100 µL of DMSO 
was added to solubilize cells and dye.  After a 10 min incubation, absorbance was read at 570 
nm using a plate reader, and the values of blank wells were averaged and subtracted from 
samples.  Untreated conditions served as positive controls from which viability was 
calculated. 
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2.12 Statistical Analysis 
Statistical analysis was performed using GraphPad Prism 4 (GraphPad Software; San Diego, 
United States).  Results were considered statistically significant if p ≤ 0.05 for either t-test or 
one-way ANOVA followed by a Tukey’s post hoc test, as stated in the figure legend.  Data 
are presented as means ± SEM, where error bars denote biological variations between 
experiments.  Colocalization was assessed using the JACoP plugin for ImageJ to determine 
Pearson’s coefficients to numerically define the degree of overlap between red and green 
channels. 
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Chapter 3: Results 
3.1 The role of CTSB in influenza A virus entry and replication  
Recent work in our lab identified CTSB as a requirement for HIV release and the 
propagation of IVA [137].  Additionally, CTSB has been shown to be indispensable in the 
lifecycles of other viruses [136, 138, 151, 153, 154, 156-158].  The majority of these viruses 
require the catalytic activity of CTSB to activate proteins used for entry into the cell or 
escape from endocytic compartments post-internalization.  To assess the role of CTSB on the 
entry and replication of IVA, cells with and without functional CTSB were infected in the 
presence or absence of an IVA replication inhibitor (Actinomycin D; ActD), which facilitates 
discrimination between virions from the inoculum and those produced via replication.  For 
this purpose, two cell lines were selected: CTSB+/+ (Wt) and CTSB-/- (KO) C57 BMDIM, as 
well as A549 human lung adenocarcinoma cells with and without the CTSB inhibitor CA-
074 Me (CaMe). Total RNA was harvested from infected cell lysates and the extent of viral 
entry and replication was determined by measuring the concentration of viral genes using 
RT-qPCR.   
IVA genes are packaged in equal quantities, with a single copy of each per virion [179, 180].  
Therefore, since copy numbers between genes are expected to be similar, two viral genes 
were quantified for each sample to enhance the validity of these measurements: a region of 
the hemagglutinin (HA) gene specific to the PR8 strain of IVA, and a region in the matrix 
(MA) gene reported to be highly conserved among IVA subtypes [173].   
To convert Ct values obtained from RT-qPCR into copy numbers for each gene, a reference 
containing known concentrations of each amplicon was generated.  Amplicons for each gene 
were PCR amplified from infected cells using respective primers.  Gel-purified amplicons 
were then quantitated using spectrophotometry, serially diluted ten-fold, and subjected to 
qPCR as described in Section 2.5.  Ct values were plotted against the concentration of each 
dilution and the equation generated from a trendline was used to calculate the concentration 
of unknown samples on the basis of Ct values (Figure 3).  Using the known size of each 
amplicon, the concentration could then be converted into the copy number of that gene.  
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Figure 3 – Standard curves of qPCR Ct values for known concentrations of amplicon. 
Gel-purified PCR amplicons generated from HA and MA primer pairs (top) were quantified 
and serially diluted ten-fold.  The dilution series was then subjected to qPCR as described in 
“Methods” to obtain Ct values corresponding to the amplicon concentration (bottom).  The 
concentration and subsequently the copy number of each viral gene was calculated using the 
equations generated by the standard curves.  Both primer pairs had efficiencies greater than 
99%. 
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3.1.1 CTSB is not required for influenza virus entry and replication in BMDIM 
cells  
Since genetic knockouts are considered the gold standard for assessing the function of a 
gene, initial experiments employed the use of a murine CTSB knockout cell line previously 
generated in the lab [137].   
As shown in Figure 4, copy numbers of HA and MA were not significantly different between 
Wt and KO cells in the presence or absence of ActD.  ActD treatment showed no significant 
differences in viability between Wt and KO cells (Figure 5A).  As expected, copy numbers of 
HA and MA genes closely resembled each other, with the exception of untreated KO cells. 
3.1.2 CTSB is not required for influenza virus entry and replication in A549 cells  
In addition to using a knockout cell line, these findings were then assessed using a more 
physiologically relevant cell type: A549 human lung adenocarcinoma cells.  A549 cells more 
closely approximate the respiratory epithelium which is infected in vivo, and as such are 
commonly used in influenza research [181-186].  Since a knockout in this cell line was 
unavailable, CTSB was pharmacologically inhibited using the cell-permeable drug CaMe 
[136-139]. 
As shown in Figure 6, there were no significant differences in HA or MA copy numbers 
between untreated cells (0 µM) and cells treated with different concentrations of CaMe, both 
in the presence and absence of ActD.  ActD treatment showed no significant difference in 
cell viability (Figure 5B).  As expected, copy numbers of HA and MA closely resembled 
each other for all samples. 
3.2 The role of CTSB in viral HA protein production 
Since CTSB was involved in neither viral entry nor replication, the next stage in the viral 
lifecycle, protein synthesis, was examined.  To this end, cell lysates of IVA-infected C57 Wt 
and KO cells, as well as A549 cells in the presence or absence of CaMe, were subjected to 
Western blotting for viral HA protein.  Densitometric analysis of the immunoreactive bands 
was performed and the intensities were normalized to those of β-actin. 
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Figure 4 – Viral entry and replication are not significantly different between wildtype 
and CTSB-/- cells.  
BMDIM from C57BL/6j mice either with (Wt) or lacking (KO) a functional CTSB gene 
were infected with influenza A virus strain PR8 for six hours at an MOI of 1 in the presence 
or absence of actinomycin D (ActD; 5 µg/mL), a transcription inhibitor.  Following infection, 
cells were harvested and extracted RNA was used as a template for qPCR reactions using 
virus-specific primers for hemagglutinin (HA; PR8-specific) and matrix protein (MA; pan-
specific).  ActD is a potent inhibitor of influenza virus replication, and therefore this 
treatment allows for the detection of incoming viral RNA while excluding that generated 
during infection.  A standard curve of purified template was used to generate copy numbers 
for each gene (Figure 3); since viral genes are packaged at a 1:1 ratio, copy numbers of HA 
and MA are directly correlated, and are indicative of the number of viral particles present.  
(A&B) There were no significant differences (p > 0.05; one-way ANOVA) in copy number 
between Wt and KO cells in viral endocytosis (ActD+) or viral replication (ActD-) for either 
the HA (A) or MA (B) gene (n≥3).  Data are expressed as means ± SEM from at least three 
independent experiments.  Columns accompanied by the same letter are not significantly 
different from each other by Tukey’s post hoc test. 
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Figure 5 – Toxicity of ActD in C57 and A549 cells. 
Wt and KO C57 cells (A) and A549 cells (B) were treated in the presence or absence of 5 
µg/mL ActD for six hours, emulating the conditions used in this study.  After incubation, an 
MTT assay was performed and the cell death measured.  (A&B) No significant differences in 
cell death were detected between Wt and KO cells, nor between treated and untreated A549 
cells (p > 0.05; t-test; n=3).  Data are expressed as means ± SEM.  N.S. = not significant. 
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Figure 6 – Viral entry and replication are not significantly different in CaMe-treated 
A549 cells. 
A549 lung adenocarcinoma cells treated with different concentrations of the CTSB inhibitor 
CaMe were infected with influenza A virus strain PR8 for six hours at an MOI of 1 in the 
presence or absence of actinomycin D (ActD; 5 µg/mL), a transcription inhibitor.  Following 
infection, cells were harvested and extracted RNA was used as a template for qPCR reactions 
using virus-specific primers for hemagglutinin (HA; PR8-specific) and matrix protein (MA; 
pan-specific).  Actinomycin D is a potent inhibitor of influenza virus replication, and 
therefore this treatment allows for the detection of incoming viral RNA while excluding that 
generated during infection.  A standard curve of purified template was used to generate copy 
numbers for each gene (Figure 3); since viral genes are packaged at a 1:1 ratio, copy numbers 
of HA and MA are directly correlated, and are indicative of the number of viral particles 
present.  (A&B) There were no significant differences (p > 0.05; one-way ANOVA) in copy 
number between untreated A549 cells and any of the tested concentrations of CaMe for either 
the HA (A) or the MA (B) gene in the presence or absence of ActD (n≥3).  Data are 
expressed as means ± SEM from at least three independent experiments.  Columns 
accompanied by the same letter are not significantly different from each other by Tukey’s 
post hoc test. 
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3.2.1 A deficiency in CTSB reduces viral HA protein production in BMDIM cells 
Since there were no significant differences in viral entry or replication, I next investigated 
whether protein production was defective.  As shown in Figure 7, the amount of viral HA 
protein detected in the lysates of infected KO cells was significantly reduced relative to Wt 
cells.  Similar results were also obtained using primary cells from mice of the same 
genotypes used to generate the cell lines (Figure 8). 
3.2.2 A deficiency in CTSB reduces viral HA protein production in A549 cells 
Viral HA protein production was also assessed in A549 cells treated with different 
concentrations of CaMe.  Similar to findings obtained in the KO cell line, 150 µM CaMe 
treatment significantly reduced HA protein levels compared to untreated cells (Figure 9B).  A 
vehicle control showed no differences in HA protein compared to untreated cells (Figure 10).  
CaMe treated cells showed no significant differences in viability compared with untreated 
controls (Figure 11). 
3.3 Pharmacological inhibition of CTSB reduces surface expression of HA 
protein on infected cells 
After synthesis, HA is trafficked to the host plasma membrane via the Golgi network where it 
is embedded on the cell surface [87].  Since CTSB inhibition or deficiency reduced HA 
protein levels in infected cells, it was important to investigate whether transport of HA to the 
cell surface was impacted.  To this end, A549 cells were infected in the presence or absence 
of either CaMe or ActD, stained for viral HA and examined by either immunofluorescence 
(Figure 12A) or confocal microscopy (Figure 12B-D). 
As shown in Figure 12A, infection of untreated cells yielded a diffuse staining pattern for HA 
(green) across the cell.  Treatment with 5 µg/mL ActD abolished this staining, and instead 
only sparse puncta were visible.  Similarly, cells infected in the presence of 150 µM CaMe 
showed puncta upon staining as well. 
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Figure 7 – CTSB-/- cells produce significantly less viral HA protein.  
BMDIM from C57BL/6j mice either with (Wt) or lacking (KO) a functional CTSB gene 
were infected with influenza A virus strain PR8 for six hours at an MOI of 1.  Following 
infection, cells were harvested, lysed and subjected to Western blotting for the influenza HA 
protein, and the resulting blots were used for densitometric analysis to express the density of 
HA normalized to actin.  (A) A representative Western blot for HA protein in cell lysates.  
(B) Infected KO cells had significantly less (p = 0.05; t-test) HA protein compared to Wt 
cells (n=3).  Data are expressed as means ± SEM from three independent experiments. 
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Figure 8 – Primary CTSB-/- cells produce less viral HA protein compared with Wt. 
Monocyte-derived macrophages from the bone marrow of C57 mice either with (Wt) or 
lacking (KO) a functional CTSB gene were infected with influenza A virus strain PR8 (+) for 
six hours at an MOI of 1.  Uninfected controls (-) from both the 6 h and 0 h time points were 
also collected for each cell type.  Following infection, cells were harvested, lysed and 
subjected to Western blotting for the influenza HA protein.  KO cells showed less HA protein 
compared to Wt (n=2). 
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Figure 9 – A549 cells treated with 150 µM CaMe produce significantly less viral HA 
protein. 
A549 lung adenocarcinoma cells treated with different concentrations of the CTSB inhibitor 
CaMe were infected with influenza A virus strain PR8 for six hours at an MOI of 1.  
Following infection, cells were harvested, lysed and subjected to Western blotting for the 
influenza HA protein, and the resulting blots were used for densitometric analysis to express 
the density of HA normalized to actin.  (A) A representative Western blot for HA protein in 
cell lysates.  (B) A549 cells treated with 150 µM CaMe showed significantly less (p < 0.05; 
one-way ANOVA) HA protein compared to untreated controls (n=4).  Data are expressed as 
means ± SEM from four independent experiments.  Columns accompanied by the same letter 
are not significantly different from each other by Tukey’s post hoc test. 
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Figure 10 – Vehicle control for CaMe treatment of A549 cells. 
A549 cells were infected with PR8 (+) at an MOI of 1 in the presence or absence of DMSO 
equivalent to 150 µM CaMe treatment as described in Methods.  An uninfected control (-) 
received PBS instead of virus.  After six hours, cells were washed and lysates were probed 
for viral HA protein contents and β-actin by Western blotting.   
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Figure 11 – Toxicity of CaMe in A549 cells. 
A549 cells were treated in the presence or absence of CaMe at the concentrations used in this 
study for six hours.  After incubation, an MTT assay was performed and the cell death 
measured.  No significant cell death was detected for any treatments (p > 0.05; one-way 
ANOVA; n=3).  Data are expressed as means ± SEM.  Columns accompanied by the same 
letter are not significantly different from each other by Tukey’s post hoc test. 
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Figure 12 – Inhibition of CTSB in A549 cells with 150 µM CaMe reduces surface 
expression of HA protein.  
Coverslips with adherent A549 cells were infected for six hours at a high MOI (>10) in the 
presence of PBS (A top left, B), CaMe (150 µM; A top right, C), ActD (5 µg/mL; A bottom 
left, D) or CaMe and ActD (A lower right).  At 5.5 h, LysoTracker Red was added to a final 
concentration of 200 nM and allowed to incubate for 30 min.  At 6 h, coverslips were 
removed from virus-containing medium, fixed in 4% formaldehyde, and blocked in PBS + 
1% BSA + 0.05% Tween 20 for 1 h.  Coverslips were then incubated in anti-HA primary 
antibody at a 1:10 dilution overnight at 4˚C.  The following day, slides were washed in PBS 
and incubated in secondary (anti-mouse FITC) at a 1:100 dilution for 2 h.  Slides were then 
washed once more and incubated in Hoechst 33342 for 3 min at a 1:4000 dilution, rinsed, 
mounted, and viewed using a Bio-Rad Radiance 2000 fluorescence microscope (A) or a Zeiss 
LSM 510 confocal fluorescence microscope (B-D).  Images shown are representative cells 
from respective treatments from three independent experiments.  (A) Untreated cells showed 
diffuse staining for HA (green) across the cell surface.  Cells treated with either CaMe or 
ActD showed no such staining, and instead showed puncta on the surface of the cell.  (B) 
Untreated cells showed diffuse staining for HA (green) across the cell membrane.  (C&D) 
Cells treated with either CaMe (C) or ActD (D) showed no such staining, and instead showed 
puncta on the cell periphery.   
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To better examine the location of these puncta on non-permeabilized cells and to further 
characterize their nature, confocal microscopy was employed to visualize single focal planes 
of specimens.  As shown in Figure 12B-D, staining for HA (green) was abundant at the 
membranes of most untreated cells.  However, cells treated with either CaMe or ActD did not 
show staining around the periphery of the cell, and instead showed puncta at the cell surface. 
3.4 Pharmacological inhibition of CTSB reduces intracellular HA protein in 
infected cells 
Since surface presentation of HA was impaired upon CTSB inhibition, I next investigated the 
localization of HA within infected cells.  The observed lack of HA protein at the cell surface 
may have been due to problems with protein trafficking.  Since CTSB has been shown to 
have a role in trafficking functions [112, 187], it is plausible that its inhibition may disrupt 
membrane transport of HA, subsequently targeting cargo for destruction in lysosomes [188-
190].  To this end, A549 cells were infected as in Section 3.3, permeabilized, and 
subsequently stained for both HA (green) and acidified endosomes/lysosomes with the dye 
LysoTracker (red).   
As shown in Figure 13, CaMe-treated cells showed significantly less intracellular staining for 
HA when compared to untreated cells; ActD-treated cells showed no intracellular staining.  
Furthermore, there was no apparent colocalization between HA protein and acidified 
endosomes in any of the conditions (Pearson’s coefficients = 0.057, 0.082 and 0.003 for 
untreated, CaMe-treated and ActD-treated cells, respectively). 
3.5 Cholesterol does not accumulate in a CTSB-dependent manner 
A growing body of evidence suggests CTSB and other cathepsins are involved in lipid 
metabolism [161, 162]; recent work has implicated cathepsin D in cholesterol transport from 
endocytic compartments to the plasma membrane [164, 165].  In the absence of certain 
cathepsins, including CTSB, lipid metabolism is attenuated, resulting in lipid accumulation in 
endosomes and/or lysosomes [163].  Many aspects of the influenza lifecycle require a 
carefully balanced quantity of cholesterol, including entry into host cells [191], progeny  
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Figure 13 – Inhibition of CTSB in A549 cells with 150 µM CaMe reduces intracellular 
expression of HA protein.  
Coverslips with adherent A549 cells were infected for six hours at a high MOI (5) in the 
presence of PBS (A), CaMe (150 µM; B), or ActD (5 µg/mL; C).  At 5.5 h, LysoTracker Red 
was added to a final concentration of 200 nM and allowed to incubate for 30 min.  At 6 h, 
coverslips were removed from virus-containing medium and fixed in 4% formaldehyde, 
permeabilized in 0.25% Triton X-100 for 10 min, and blocked in PBS + 1% BSA + 0.05% 
Tween 20 for 1 h.  Coverslips were then incubated in anti-HA primary antibody at a 1:10 
dilution overnight at 4˚C.  The following day, slides were washed in PBS and incubated in 
secondary (anti-mouse FITC) at a 1:100 dilution for 2 h.  Slides were then washed once more 
and incubated in Hoechst 33342 for 3 min at a 1:4000 dilution, rinsed, mounted, and viewed 
using a Zeiss LSM 510 confocal fluorescence microscope.  Images shown are representative 
cells from respective treatments from three independent experiments, and adjacent images 
from different z-stack layers (depths).  (A) Untreated cells showed an abundance of HA 
(green) as puncta throughout the cell, in the vicinity of acidified endosomes in the cytoplasm 
(LysoTracker; red).  (B) Cells treated with CaMe show less puncta inside infected cells.  (C) 
ActD-treated cells showed no intracellular puncta, as expected.  (D) When the number of 
puncta per cell in at least three random fields of view were quantified, CaMe-treated cells 
had significantly fewer puncta per cell relative to untreated cells (p > 0.05; one-way 
ANOVA; n=3).  Data are expressed as means ± SEM.  Columns accompanied by the same 
letter are not significantly different from each other by Tukey’s post hoc test.  
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virion assembly and budding [66, 85, 104, 192], the virulence of progeny virus particles 
[193, 194], and membrane transport of HA [106, 195], neuraminidase [80] and nucleoprotein 
[196].  Disruptions at any of these stages could result in a marked decrease in viral 
proliferation.  Given the possibility that CTSB is involved in maintaining lipid homeostasis 
within the cell, it was pertinent to assess whether cholesterol accumulation occurs in its 
absence, and subsequently whether this was the mechanism responsible for the decreased 
viral proliferation observed in these cells.   
To assess whether a CTSB-deficiency was resulting in the accumulation of cholesterol within 
endosomes, C57 Wt and KO cells were subjected to sub-cellular fractionation to yield two 
collections of intracellular components: a crude fraction containing mitochondria, lysosomes, 
peroxisomes, endoplasmic reticulum and late endosomes; and a purified fraction containing 
late endosomes and lysosomes.  Samples were then assessed for their cholesterol content 
using the Amplex Red cholesterol assay kit, and values were normalized to those obtained 
from a Bradford protein assay. 
As shown in Figure 14, normalized cholesterol concentrations were not significantly different 
between Wt and KO cells for either crude organelle or purified endosome/lysosome 
preparations. 
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Figure 14 – Endosomal cholesterol accumulation is not responsible for CTSB-
dependent influenza A virus restriction.  
Wt and KO cells were mechanically homogenized and subjected to differential centrifugation 
at a low speed (1000 g) to pellet nuclei and cell debris followed by a high speed (20000 g) to 
pellet organelles (mitochondria, lysosomes, peroxisomes, endoplasmic reticulum, late 
endosomes; A).  Half of this preparation was then further purified by calcium ion 
precipitation to yield a fraction containing lysosomes and late endosomes (B).  Both fractions 
were then assayed for cholesterol and protein concentration, and cholesterol concentration 
was normalized to protein content.  (A&B) When compared to Wt, KO cells showed no 
significant difference (p > 0.05; paired t-test) in the normalized cholesterol concentrations in 
either organelle (A) or endosomal (B) fractions (n=3).  Data are expressed as means ± SEM.  
N.S. = not significant. 
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Chapter 4: Discussion 
4.1 CTSB is not required for influenza A virus entry or replication  
Recent work in our lab identified CTSB as a requirement for HIV release and the 
propagation of IVA [137].  Cells infected with IVA in the presence of CaMe showed a 
significant reduction in immunofluorescence compared to untreated cells when stained with 
pan-specific antibodies against the virus.  Work by others indicates CTSB is a requirement in 
the lifecycles of adeno-associated virus [158], Ebola virus [151, 153, 154], reovirus [136], 
Nipah virus [156], coronavirus [157], and Moloney murine leukemia virus [138].  In most 
cases, the role of CTSB is to proteolytically activate viral proteins which facilitate escape 
into the cytoplasm following endocytosis.  Given that CTSB is found mainly in endosomes 
and IVA uses endosomes to enter host cells, I investigated the role of CTSB in the early 
stages of the viral lifecycle.  Inability of virions to be endocytosed or escape from endosomes 
could explain the reduction in viral propagation observed previously [137].  To this end, viral 
load was measured by RT-qPCR in infected cells in the presence or absence of an IVA 
replication inhibitor, actinomycin D (ActD). 
ActD is a transcriptional inhibitor that has been used extensively in influenza research [197-
202].  At an appropriate concentration, the drug effectively blocks influenza virus replication 
(Appendix 1) by preventing nuclear import of the viral genome [198].  Therefore, cells 
treated with ActD contain only the genetic material and viral proteins endocytosed from the 
original inoculum, affording an accurate means of assessing viral endocytosis in the absence 
of replication.  RT-qPCR has proven to be a useful tool in quantifying influenza particles 
[171-173, 203-205].  This is due in part to its sensitivity and the genetic nature of the virus, 
which packages one copy of each viral gene per virion [179, 180].  Thus, calculations of 
copy number accurately reflect the absolute number of virions present.   
When copy numbers of HA and MA were quantified for infected BMDIM, there were no 
significant differences between Wt and KO in the copy number of either HA or MA in either 
the presence or absence of ActD (Figure 4).  This data indicates that both Wt and KO cells 
have similar amounts of viral genetic material after entry (ActD+) and during the early stages 
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of replication (ActD-), suggesting that virion entry into these cells and subsequent replication 
does not require CTSB. 
An identical experiment was performed using the more physiologically relevant A549 lung 
epithelial cell line and the CTSB inhibitor CaMe at three different concentrations.  Similar to 
findings in the C57 cell line, there were no significant differences in the copy numbers of HA 
or MA between untreated A549 cells and any of the doses of CaMe both in the presence or 
absence of ActD (Figure 6).  
As expected, cells treated with ActD show a reduction in the copy number of both genes 
quantified compared to untreated cells, reflecting the drug’s ability to inhibit virus replication 
(Appendix 1).  However, one notable difference between the two cell lines used is the titres 
both achieve.  Titres for infected A549 cells in the presence of ActD approach, but never 
reach 105 copies, reflecting approximately 10% of the total number of virus particles used to 
infect the cells (106 for an MOI of 1).  Surprisingly, BMDIM under the same conditions 
routinely reach titres of ~2 x 107 copies, approximately twenty-fold more copies than the 
inoculum contained.  This inconsistency can likely be attributed to the fact that C57 cells are 
macrophages, and as such will phagocytose pathogens such as influenza virions.  When the 
stock viral inoculum was titred using the above method, it was found that there were 
approximately 5 x 105 copies of HA and 4 x 105 copies of MA for every titred virion 
(Appendix 2).  Thus, with approximately 4.0 – 5.0 x 1011 copies per gene present at an MOI 
of 1, it is conceivable that a macrophage could engulf ~2.0 x 107 copies.  As a result, values 
for viral entry in BMDIM are likely to be overestimates compared with A549 cells, which are 
epithelial cells and not phagocytes, and therefore require functional, infectious virions to 
deliver viral genes to the cell. 
The presence of such a large amount of genetic material in the inoculum can be explained by 
the propensity of influenza virus to generate defective particles in culture [206-208].  The 
observation of incomplete and non-infectious influenza particles is not a new phenomenon; 
first documented in the 1950s, it has now become apparent that these structures are produced 
in the culture of several animal viruses [206, 207].  Indeed, some viruses have been shown to 
produce several thousand non-infectious particles for every one infectious particle [209].  In 
the case of influenza, it is believed that the error-prone RNA synthesis of genomes can result 
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in the generation of mutants lacking important genes for replication [210].  Since these 
mutants have less genetic material, they replicate faster than Wt virus, and can quickly 
accumulate when propagated in culture.  It is likely that the viral inoculum used in this study 
experienced this fate during its production. 
An additional inconsistency between the two cell types is the titre they achieve during active 
replication.  During the six-hour infection period, unabated replication in BMDIM yielded  
~7 x 107 copies of HA and MA, whereas A549 cells yielded ~3 x 108 copies.  This may 
reflect the permissiveness of the respective cell type to infection; evidence suggests that 
influenza replicates to higher titres in epithelial cells than macrophages [211]. 
A final variation is evident in the copy numbers of HA and MA from KO cells in the absence 
of ActD, thereby measuring active replication.  Although not statistically significant, the 
mean copy number of KO MA (3.9 x 107 ± 1.4 x 107) was nearly half those of KO HA, Wt 
HA and MA (6.8 x 107 – 7.7 x 107 ± 2.1 x 107).  The nature of this discrepancy is unclear; 
replication in BMDIM as measured by the HA gene showed no such aberration, nor did 
A549 cells for either gene (Figure 4 & Figure 6).  Since this was the only incidence where 
the copy numbers of HA and MA were not similar, values for this specific treatment should 
be interpreted with caution. 
4.2 A deficiency in CTSB reduces viral HA protein production 
After entry and replication, the next logical step to examine is the synthesis of viral proteins.  
To this end, lysates of infected C57 Wt and KO cells, as well as A549 cells in the presence of 
different concentrations of CaMe, were separated by SDS-PAGE and probed for viral HA 
protein by Western blot. 
The choice to examine HA over other viral proteins in this and following experiments was 
twofold.  First, HA is absolutely crucial for infectivity [45]; although not obligatory for 
assembly and release of viral particles [212], virions lacking HA are non-infectious [110] due 
to an inability to bind host cells or escape endosomes following endocytosis.  Second, 
although HA is not the most abundant protein in virions [185], it is nonetheless produced in 
modest quantities and composes ~80 % of the protein on virion envelopes [37, 87].  Since the 
spike glycoprotein is present both inside cells and on the plasma membrane, HA is a 
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pragmatic choice as it affords the ability to assess the outcomes of infection in both 
compartments. 
2.5 hours post-infection, the background of host proteins is dramatically reduced as the 
machinery is usurped for the production of viral proteins [213-215].  At 3.5 hours post-
infection, most viral proteins, including HA, can be easily detected inside infected cells, and 
have synthesis rates which remain stable up to 10 hours post-infection.   
When the concentration of HA protein was examined in cells 6 hours post-infection, strong 
immunoreactivities were detected in lysates of both C57 (Figure 7) and A549 (Figure 9) 
cells.  The density of these bands was quantified and normalized to those of actin to yield a 
density for HA which accounted for loading differences between samples.  In contrast to 
entry and replication, C57 KO cells produced significantly less HA protein than Wt cells.  
This reduction was also evident in infected primary cells of the same genotypes (Figure 8).  
Likewise, A549 cells treated with 150 µM CaMe produced significantly less HA than 
untreated cells; a dose dependent reduction in HA protein was evident, but only the 150 µM 
CaMe treatment reached statistical significance.  This reduction was not caused by a decrease 
in viability as a result of the CaMe treatment (Figure 11).   
It is important to note that even the genetic knockout showed some HA protein (Figure 7), 
suggesting that these cells were, albeit to a lesser extent, still permissive to viral HA 
production.  Thus, it can be concluded that CTSB is required for optimal viral HA protein 
production.   
4.3 Pharmacological inhibition of CTSB reduces surface expression of HA 
protein on infected cells 
After synthesis, HA is trafficked via the Golgi to the plasma membrane where it is embedded 
[87, 103]; budding virions simultaneously acquire both a lipid envelope and anchored HA 
upon egress from infected cells, thus endowing them with the ability to infect new host cells.  
Since the amount of HA protein is significantly reduced in CTSB-deficient cells relative to 
wildtype, it was important to investigate the fate of the HA protein in these cells.  It is 
plausible that differences in the amount of HA protein will impact the amount successfully 
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transported to the cell surface, and therefore onto progeny virions.  Since HA is a critical 
requirement of infection, alterations in the HA protein present on virion envelopes may have 
important consequences on the virulence of progeny. 
To examine the downstream consequences of this reduction in intracellular HA protein, 
A549 cells were infected in the presence or absence of CaMe, ActD or a combination of the 
two, and stained for viral HA.  Cells were then observed by both immunofluorescence and 
confocal microscopy to assess the amount of HA on the plasma membrane.  A549 cells were 
selected for these studies because they appeared to yield higher viral titres when compared to 
C57 cells (Figure 6).  Additionally, these cells possess an epithelial morphology, making 
them larger than macrophages, and therefore facilitate better visualization by microscopy.  A 
single CaMe dose of 150 µM was selected because it yielded a significant reduction in HA 
protein by Western blot (Figure 9).  Finally, since protein synthesis and surface presentation 
kinetics vary with MOI, a higher MOI was selected for microscopy experiments to not only 
ensure all cells were infected, but improve the probability of protein expression on the cell 
surface within a 6 hour infection period [216].  Indeed, fewer cells showed fluorescence for 
surface HA when infected at an MOI of 1 for 6 hours (data not shown). 
When observed using immunofluorescence microscopy, untreated cells showed a diffuse 
staining pattern for HA across the plasma membrane after infection (Figure 12A); this 
finding reflects the proper transport of newly synthesized viral HA to the cell surface, where 
it will be incorporated in the envelopes of budding progeny.  However, this staining pattern 
was not observed in cells treated with ActD (5 µg/mL), CaMe (150 µM) or a combination of 
the two; instead, only sparse areas of fluorescent puncta were visible on the surface of 
infected cells.   
Since the nature of these puncta remained unclear by immunofluorescence microscopy alone, 
confocal microscopy was used to examine single focal planes of cells to rule out the 
possibility that they were simply debris or artefacts in the preparation, rather than the cells 
themselves.  When specimens were prepared and observed using confocal microscopy, a 
similar staining pattern was observed (Figure 12B-D).  As expected, untreated cells showed 
abundant staining for HA protein across the plasma membrane upon infection with IVA.  
Interestingly, similar to Figure 12A, CaMe- and ActD-treated cells showed no diffuse 
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staining across the periphery of the cell, but puncta in limited areas of the membrane.  It is 
important to note that these puncta are observable in the same focal plane as intracellular 
organelles (lysosomes, red; nucleus, blue), but adjacent to the cells themselves.   
The absence of HA on the membranes of ActD-treated cells conforms to expectations; since 
no HA protein is produced in this treatment (Appendix 1), logic dictates that no protein will 
be presented on the surface of these infected cells.  Strikingly, CaMe-treated cells showed a 
very similar phenotype, suggesting that they too failed to present HA on the cell surface.  
However, unlike ActD-treated cells, HA was indeed present in CaMe-treated cells, albeit at 
lower concentrations than in untreated controls (Figure 9). 
The puncta on the surface of CaMe- and ActD-treated cells are not likely the result of viral 
activity.  Since ActD treatment abolished both replication (Figure 6) and HA protein 
production (Appendix 1), it is doubtful these puncta represent HA originating from within 
infected cells.  As similar puncta were observed in CaMe-treated cells, it is conceivable that 
these too resulted from a phenomenon external to infection.  This notion is supported by the 
presence of similar puncta in control conditions which lack primary (anti-HA) antibody 
(Appendix 3), suggesting they may be the product of non-specific binding of the secondary 
antibody.  Additionally, it is also possible that large numbers of defective particles in the 
inoculum aggregated at the cell surface, where they were subsequently fixed and stained. 
Nonetheless, it is clear that CaMe-treatment impaired the surface presentation of HA protein.  
Collectively, these data suggest that in addition to optimal HA protein production, CTSB is 
also a requisite for proper presentation of HA on the surface of infected cells.  However, this 
observation fails to explain the apparent discrepancy between the levels of intracellular HA 
protein and that presented on the surface of CaMe-treated infected cells.  Were HA 
presentation a mere function of the intracellular concentration of the protein, a reduction in 
intracellular HA would be expected to reduce surface expression of the protein in a 
proportional manner.  However, these data show a complete absence of observable HA on 
the surface of CaMe-treated infected cells in spite of having detectable levels of HA protein 
(Figure 9).  This suggests that an additional CTSB-dependent mechanism is involved in the 
successful translocation of HA protein to the surface of infected cells. 
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4.4 Pharmacological inhibition of CTSB reduces intracellular HA protein in 
infected cells 
While the effects of CTSB-inhibition on intracellular (Figure 9) and membrane-associated 
(Figure 12) HA protein were apparent, the cause of these reductions remained elusive.  
Indeed, several possible explanations exist, thus necessitating a more detailed examination 
into the location of HA within CaMe-treated infected cells.   
Although CTSB is commonly known for its proteolytic functions, paradoxically, the 
reduction in HA protein may be caused by its absence.  Recent research suggests that in 
addition to classically defined roles, CTSB is also involved in the trafficking of proteins 
[187] and vesicles [112].  The latter is of particular interest, as the transport of HA is 
analogous to that of TNF-α, the subject of prior research.  HA, like TNF-α, is transported 
through the Golgi to the cell surface [87, 217].  In the absence of functional CTSB, TNF-α 
failed to reach the plasma membrane, and instead accumulated in intracellular vesicles [112].  
Likewise, inhibition of CTSB resulted in a failure to release HIV-1 virus-like particles, 
instead retaining them within host cell compartments [137].  Thus, since HA failed to reach 
the membranes of CaMe-treated cells, it is possible that HA protein may be transported 
through a similar CTSB-dependent mechanism.   
However, intracellular HA protein was reduced in CTSB-deficient cells (Figure 7; Figure 9), 
making it unlikely that HA was accumulating inside vesicles as was the case for TNF-α.  One 
mechanism by which intracellular protein levels can be depleted involves lysosomal 
degradation.  Lysosomes are acidic organelles which contain a variety of enzymes used to 
digest proteins and other macromolecular structures in the cell [218].  In the context of the 
IVA lifecycle, a possible scenario in which CTSB-dependent HA transport is impaired may 
result in the inadvertent delivery of HA proteins to lysosomes, where they are subsequently 
degraded [188-190].  Instances where proteins or vesicles are improperly targeted to 
lysosomes due to defects in their respective transport systems have been noted in literature 
previously [219-221].   
Since the above scenario could potentially explain both the decrease in intracellular HA 
protein and its absence on the surface of CaMe-treated infected cells, the localization of 
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intracellular HA was assessed using confocal microscopy, particularly in regard to 
lysosomes.  To this end, A549 cells were infected in the presence or absence of CaMe and 
ActD in the same manner as cells prepared for Section 3.3 with the addition of a 
permeabilization step to allow for immunostaining of HA within cells.  Lysosomes were 
visualized using LysoTracker, a membrane-permeable fluorophore that preferentially 
accumulates in acidic organelles such as lysosomes or acidified late endosomes [222]. 
When CaMe-treated cells were examined, both the number and size of intracellular HA 
puncta were noticeably reduced when compared to untreated cells (Figure 13).  As expected, 
ActD-treated cells showed no intracellular puncta.  These observations were all in agreement 
with immunoblot analyses for HA (Figure 9; Appendix 1).  However, there was no visible 
colocalization between HA protein (green) and lysosomes (red) in any of the conditions, 
which would have been indicative by a yellow colour.  Fluorescence colocalization can also 
be mathematically quantified by means of a Pearson’s coefficient, which expresses the 
degree of overlap between two fluorescence channels in terms of a numeric value [223].  
Since a value of 0 represents a complete lack of correlation, respective Pearson’s coefficients 
of 0.057, 0.082 and 0.003 for untreated, CaMe-treated, and ActD-treated cells also support 
visual observations. 
It is worth noting that LysoTracker has been reported to undergo photoconversion under 
certain conditions [224].  The resulting green fluorescence emitted can overlap with other 
dyes at this wavelength such as FITC, which was used in labelling for HA.  However, since 
there was both minimal colocalization of these channels in all treatments, and no observable 
green fluorescence detected in most ActD-treated cells (Figure 13), it is highly unlikely this 
effect took place in this study.  As such, it is doubtful that puncta indicative of HA can be 
attributed to LysoTracker.  Additionally, there was also a noticeable reduction in membrane 
puncta between permeabilized and unpermeabilized cells (compare Figure 13C with Figure 
12D).  This can likely be attributed to the permeabilization procedure, which causes 
significant damage to the membrane, thereby increasing the chances of non-specific binding 
at the cell surface being removed. 
Collectively, these data do not substantiate the notion that lysosomal degradation is the cause 
of HA protein reduction within, and absence on the surface of CTSB-deficient cells.  An 
58 
 
 
 
alternative pathway of protein degradation – the proteosome – was also investigated as the 
cause of CTSB-dependent decreases in intracellular HA.  However, preliminary studies using 
the proteosome inhibitor MG132 did not appear to result in visible increases of HA protein in 
C57 KO cells (data not shown).  Since MG132-treatment is not a comprehensive means of 
inhibiting all protein degradation pathways, degradation of HA protein in CTSB-deficient 
cells remains a possibility.  Thus, an alternate mechanism is the source of intracellular HA 
protein reduction and/or unsuccessful transport to the plasma membrane of CaMe-treated 
infected cells. 
4.5 Cholesterol does not accumulate in a CTSB-dependent manner 
Since lysosomal intervention was uninvolved in the fate of HA protein in CTSB-deficient 
cells, a new mechanism was sought to explain the differences in HA expression between 
cells with and without functional CTSB.  A more exotic postulate for this phenomenon may 
involve transport systems for lipids such as cholesterol.   
Recent work implicates CTSB and other members of the cathepsin family are involved in the 
metabolism of lipids [161, 162]; for example, cathepsin D has been implicated in cholesterol 
transport from endocytic compartments to the plasma membrane [164, 165].  Importantly, the 
absence of certain cathepsins, such as CTSB, results in the attenuation of lipid metabolism 
and accumulation of lipids in endocytic vesicles and/or lysosomes [163].  A functionally 
homologous condition can be found in cells bearing mutations in the gene NPC1, resulting in 
Niemann-Pick disease, type C.  NPC1 is an intracellular cholesterol transporter; loss of 
function results in a dramatic accumulation of lipids in late endosomes and lysosomes and 
aberrant trafficking of these vesicles [165-169]. 
Interestingly, human immunodeficiency virus (HIV) release is impaired in NPC1-/- cells 
[225]; this was accompanied by a concomitant trapping of the viral structural protein, Gag, 
inside endosomes and lysosomes [226].  Another enveloped virus, Ebola virus, showed an 
inability to infect NPC1-/- cells due to a failure in escaping from endosomes following entry 
into host cells [227, 228]. 
Cholesterol is a lipid sterol that is essential for the maintenance of membrane dynamics, 
fluidity and permeability, among other functions [229].  Given that IVA is an enveloped 
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virus, is it perhaps not surprising that it also shares a similar dependence on cholesterol levels 
which are adequate, but not excessive. 
Indeed, several facets in the influenza lifecycle can be affected by changes in cholesterol.  
Cholesterol is critical for IVA virion entry; depletion of viral envelopes significantly reduces 
virion infectivity, possibly by disrupting the fusion process [191].  Additionally, cholesterol 
is a major constituent of lipid rafts, microdomains in the plasma membrane which serve as 
sites for virion assembly and budding [85, 104, 108, 192].  As such, multiple viral proteins 
are targeted here, including nucleoprotein cores [196] and spike glycoproteins neuraminidase 
[80] and HA [106, 195].  It is postulated that lipid rafts facilitate the concentration of viral 
proteins in order to reach sufficient concentrations for assembly and budding; in the case of 
HA, it is thought that this strategy ensures adequate protein will be present on the envelopes 
of budding progeny to effectively mediate membrane fusion with a new host cell [66]. 
Disrupting lipid rafts by cholesterol depletion reportedly enhanced the release of viral 
particles, but these particles displayed reduced infectivity [193].  The authors proposed this 
was the result of multiple consequences associated with cholesterol reduction, such as altered 
structural integrity of virions or the stability of their membranes.  Interestingly, the 
interferon-inducible antiviral protein viperin inhibits the release of IVA virions by disrupting 
lipid rafts [230].  Finally, the use of cholesterol-reducing drugs in vivo has also been linked to 
a decrease in mortality as a result of influenza infection, though the observational study did 
not propose a mechanism for this [231, 232]. 
Considering that obstructions to any of the above processes may result in a marked decrease 
in viral proliferation, including problems targeting HA to the membrane, it was pertinent to 
investigate whether observations in CTSB-deficient cells are a consequence of cholesterol 
dysregulation.  The endosomal accumulation of lipids like cholesterol may not only result in 
improper trafficking of vesicles containing viral components, but may also reflect an 
impairment of cholesterol transport to the membrane, thus affecting lipid rafts as well. 
To assess the role of CTSB in the accumulation of cholesterol within endosomes, C57 Wt 
and KO cells were fractionated to yield subcellular organelles, and both cholesterol and 
protein contents were quantified using Amplex Red and Bradford assays, respectively. 
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When Wt and KO cells were compared, normalized cholesterol concentrations were not 
significantly different for either the crude or purified preparations (Figure 14).  The finding 
that cholesterol is similar in both fractions between these cell types indicates cholesterol does 
not accumulate in a CTSB-dependent manner, and consequently is unlikely to be the 
mechanism behind IVA restriction in these cells.  However, it should be noted that since this 
assay examined the cholesterol of intracellular organelles, it does not preclude the possibility 
of CTSB-dependent alterations to lipid rafts in the plasma membrane. 
4.6 Future directions 
At present, the role CTSB plays in the influenza lifecycle remains unclear.  When viral titres 
were assessed using a hemagglutination assay, there were no significant differences between 
the supernatants of A549 cells infected for 24 hours in the presence or absence of 150 µM 
CaMe (Appendix 4).  It is worth noting that a hemagglutination assay measures viral titres on 
the basis of HA protein on the surface of particles, and consequently is unable to distinguish 
between infectious and defective particles.  Thus, although particles appear to be released 
from infected cells in the presence of CaMe, and interestingly, bear comparable amounts of 
HA protein as those released from untreated cells, whether these particles are functional 
could not be definitively ascertained.  It is possible that a CTSB-deficiency delays the surface 
expression of HA, and that the longer incubation period used in the hemagglutination assay 
affords more time for its incorporation into the host membrane and subsequently budding 
virions [216].  Additionally, it would be of interest to determine whether these observations 
are unique to HA or apply to other viral proteins whose synthesis and trafficking are both 
similar (NA) and dissimilar (nucleoprotein) to HA. 
It was recently reported that influenza infection elevates CTSB in murine cells [233], which, 
in agreement with this work, suggests that it plays an important role in the viral lifecycle.  
However, the reduced intracellular, but absent surface expression of HA in CTSB-deficient 
cells remains an unresolved discrepancy.  Proposed mechanisms involving lysosomal 
degradation and cholesterol accumulation could not be substantiated as the cause of these 
phenomena.   
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It is possible that both observations could result from separate yet related processes involving 
a requirement for CTSB.  The reduction in intracellular HA could not be definitively 
attributed to post-translational degradation, nor could differences in protein synthesis be 
ruled out.  It is possible that cathepsins like CTSB function as transcriptional activators for 
viral genes such as HA [234, 235].  This could perhaps explain why a CTSB-deficiency 
attenuated HA protein levels, rather than abolish them entirely. 
Alternatively, the role of CTSB may be independent from facilitating the production and 
transport of HA to the infected cell membrane, with these observations being mere 
consequences of a different pathway.  For example, influenza has been shown to require the 
process of autophagy for optimal replication for reasons not fully understood at this time, but 
possibly involving cell death [183, 236-242].  CTSB is increasingly being connected with 
autophagy, including cell death responses [118, 187, 243-245].  Similarly, it has been shown 
the virus activates the host inflammatory response [246], possibly due to a reliance on 
caspase 3 for nuclear exit of ribonucleoprotein cores [247, 248].  If the virus relies on 
inflammasome activation to make use of caspase 3, it is of interest that CTSB has been 
reported to be involved in inflammasome activation [113, 114], the stimulation of caspase 3 
[249], and the catalytic activation of Toll-like receptor 3 [250], which IVA uses to stimulate 
the inflammasome.  Thus, there are many potential avenues in the search for mechanistic 
details of CTSB-dependent influenza virus restriction.  
Resistance of circulating IVA strains to older antivirals such as amantadine has increased at 
an alarming rate over the past decade [251]; as a result, the CDC no longer recommends the 
use of these drugs in the treatment of influenza infections [252].  Resistance to newer 
antivirals such as oseltamivir (Tamiflu®) has also been documented, in spite of earlier 
reports which erroneously suggested such resistance-conferring mutations would 
significantly compromise viral fitness as a result, making them an unlikely threat [253, 254].  
Given the rate with which antiviral therapies are becoming obsolete due to viral mutations, a 
more effective strategy would be to target host rather than viral components required for the 
effective replication of IVA.  CTSB is an essential human protease which serves a number of 
important functions within healthy cells; as such, it is not feasible to treat IVA infections 
with a CTSB-inhibitor like CaMe.  However, future work should endeavour to further 
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delineate the role of CTSB as a requirement for IVA infection and/or propagation.  Greater 
knowledge of the host systems the virus exploits within infected cells may shed light on new 
targets for antiviral therapies less prone to resistance. 
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Chapter 6: Appendices 
 
 
 
 
 
Appendix 1 – ActD blocks the production of viral HA protein at a concentration of 5 
µg/mL. 
A549 cells were infected with influenza at an MOI of 1 in the presence or absence of ActD  
(5 µg/mL) for six hours.  After infection, the cells were harvested, lysed, and subjected to 
Western blotting for HA as described in “Methods”.  There were no immunoreactivities for 
HA detected in either condition receiving ActD, indicating the viral protein was not produced 
in detectable quantities. 
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Appendix 2 – Detected copy numbers of HA and MA per titred virion in the inoculum. 
1.0 x 104 virions from the inoculum used in this study were subjected to RNA extraction as 
described in “Methods”.  One µL of the resulting RNA was used for each reverse 
transcription reaction.  cDNA was then used for qPCR amplification following the same 
conditions used for experimental procedures.  Ct values obtained were converted to copy 
numbers using the standard curve equations in Figure 3, and dilution factors were used to 
calculate the gene copies/titred virion from the original inoculum (n=3).  Data are expressed 
as means ± SEM. 
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Appendix 3 – Immunofluorescence microscopy of infected A549 cells stained with 2 
antibody (FITC) only. 
Coverslips with adherent A549 cells were infected for six hours at a high MOI (>10).  5.5 
hours post-infection, LysoTracker Red was added to a final concentration of 200 nM and 
allowed to incubate for 30 min.  At 6 hours, coverslips were removed from virus-containing 
medium, fixed in 4% formaldehyde, and blocked in PBS + 1% BSA + 0.05% Tween 20 for 1 
hour.  Coverslips were then washed in PBS and incubated in secondary antibody (anti-mouse 
FITC) at a 1:100 dilution for 2 hours.  Slides were washed once more and incubated in 
Hoechst 33342 for 3 min at a 1:4000 dilution, rinsed, mounted, and viewed using a Bio-Rad 
Radiance 2000 fluorescence microscope.   
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Appendix 4 – Hemagglutination assay of infected A549 supernatants  
1.0 x106 A549 cells were infected at an MOI of 1 as described in “Methods” in the presence 
or absence of different concentrations of CaMe in the absence of serum, which contains 
nonspecific inhibitors of IVA infection [255-258].  After 24 hours, supernatants were 
removed from monolayers and subjected to a standard hemagglutination assay using chicken 
red blood cells and a series of two-fold dilutions of the supernatants.  After a 30 min 
incubation, wells were scored as being either positive or negative for agglutination, and the 
titer expressed as the reciprocal of the highest dilution yielding agglutination.  (A) A 
representative image of hemagglutination assay results, with both negative (–) and positive 
(+) controls.  (B) There was no significant difference between the titre of untreated cells and 
cells treated with 150 µM CaMe, but 500 µM CaMe treatment showed a significant reduction 
in virus titre (p > 0.05; one-way ANOVA; n≥3).  Data are expressed as means ± SEM from at 
least three independent experiments.  Columns accompanied by the same letter are not 
significantly different from each other by Tukey’s post hoc test. 
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